Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Ikena Oncology, Inc. Banner

Ikena Oncology, Inc.

IKNA Stock Analysis

Page title

Section title

About Ikena Oncology, Inc.

Biotechnology
Healthcare

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ikena Oncology, Inc. Key Metrics

Market Cap
$81M
52 Weeks Low
$1.02
52 Weeks High
$4.95
P/B
0.56x
P/E
-1.21x
P/S
43.70x

Upcoming Events

    IKNA Analyst Forecasts

    ‌
    ‌

    IKNA Financials

    IKNA Income Statement Key Metrics

    • Revenue(TTM)1.84 M
    • Gross Profit(TTM)986,000
    • EBITDA(TTM)-71.58 M
    • Net Income(TTM)-66.71 M
    • EPS Diluted(TTM)-1.42

    Decode IKNA's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    IKNA earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of IKNA (0.889) is higher than the average of its peers (0.245).

    Net Profit Margin vs Peers

    Net profit margin ratio of IKNA (-7.442) is lower than the average of its peers (-5.834).

    IKNA Return on Equity

    See how efficiently IKNA generates profit for it's shareholders.

    -40.16%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of IKNA (-0.402) is lower than the average of its peers (-0.341).

    Return on Equity Growth

    IKNA's Return on Equity has grown significantly over the past 10 years, increasing by over 12.45%.

    IKNA Revenue Growth

    See how IKNA has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    IKNA's revenue has grown significantly over the past 10 years, increasing by over 44.89%.